Abstract

The present invention is directed to the treatment of skin erythema as exhibited in rosacea and other conditions characterized by increased erythema (redness) of the skin. These conditions exhibit dilation of blood vessels due to a cutaneous vascular hyper-reactivity. In particular, the present invention is directed to a novel composition and method for the treatment of skin erythema using α1-adrenergic receptor (α1-adrenoceptor) agonists incorporated into cosmetic, pharmacological or dermatological compositions for topical application to the skin.


Claims
Owners (US)

Information currently unavailable.

CPC Classifications
Download PDF
Document Preview
Document History
  • Publication: Aug 17, 2017
  • Application: Jun 10, 2015
    US US 201514736143 A
  • Priority: Jun 10, 2015
    US US 201514736143 A
  • Priority: Mar 13, 2013
    US US 201313800361 A
  • Priority: Oct 11, 2010
    US US 90175510 A
  • Priority: Oct 11, 2010
    US US 90191110 A
  • Priority: May 27, 2010
    US US 78874610 A
  • Priority: Jan 22, 2004
    US US 76380704 A

Sign in to the Lens